Allison M |
Can cancer clinical trials be fixed? |
2011 |
Nat. Biotechnol. |
pmid:21221090
|
Shen BQ et al. |
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. |
2012 |
Nat. Biotechnol. |
pmid:22267010
|
Beck A et al. |
Strategies and challenges for the next generation of antibody-drug conjugates. |
2017 |
Nat Rev Drug Discov |
pmid:28303026
|
Zolot RS et al. |
Antibody-drug conjugates. |
2013 |
Nat Rev Drug Discov |
pmid:23535930
|
Villanueva MT |
Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer. |
2014 |
Nat Rev Clin Oncol |
pmid:24913372
|
Kang Q et al. |
Biosynthesis of 3,5-AHBA-derived natural products. |
2012 |
Nat Prod Rep |
pmid:22193711
|
Menchon G et al. |
A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. |
2018 |
Nat Commun |
pmid:29844393
|
Adams SR et al. |
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. |
2016 |
Nat Commun |
pmid:27698471
|
Zhong P et al. |
cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. |
2017 |
Nanotechnology |
pmid:28574851
|
He X et al. |
Inflammatory Monocytes Loading Protease-Sensitive Nanoparticles Enable Lung Metastasis Targeting and Intelligent Drug Release for Anti-Metastasis Therapy. |
2017 |
Nano Lett. |
pmid:28758755
|
Teicher BA and Doroshow JH |
The promise of antibody-drug conjugates. |
2012 |
N. Engl. J. Med. |
pmid:23134386
|
Verma S et al. |
Trastuzumab emtansine for HER2-positive advanced breast cancer. |
2012 |
N. Engl. J. Med. |
pmid:23020162
|
Hamblett KJ et al. |
Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. |
2016 |
Mol. Pharm. |
pmid:27248573
|
Hong EE et al. |
Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. |
2015 |
Mol. Pharm. |
pmid:25856201
|
Widdison W et al. |
Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. |
2015 |
Mol. Pharm. |
pmid:25826705
|
Salomon PL and Singh R |
Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells. |
2015 |
Mol. Pharm. |
pmid:25738394
|
Fishkin N |
Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes. |
2015 |
Mol. Pharm. |
pmid:25738231
|
Goldmacher VS et al. |
Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. |
2015 |
Mol. Pharm. |
pmid:25635630
|
Barginear MF et al. |
Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. |
2012 |
Mol. Med. |
pmid:23196784
|
Erickson HK et al. |
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. |
2012 |
Mol. Cancer Ther. |
pmid:22408268
|